NASDAQ:VERU - Veru Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.72 -0.03 (-1.71 %) (As of 05/24/2019 07:42 AM ET)Previous Close$1.7550Today's Range$1.70 - $1.846252-Week Range$1.18 - $2.37Volume200,429 shsAverage Volume146,786 shsMarket Capitalization$108.00 millionP/E RatioN/ADividend YieldN/ABeta0.88 ProfileAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida. Receive VERU News and Ratings via Email Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Fabricated rubber products, not elsewhere classified Sub-IndustryPersonal Products SectorMedical Current SymbolNASDAQ:VERU Previous Symbol CUSIP31446210 CIK863894 Webhttp://www.veruhealthcare.com/ Phone305-509-6897Debt Debt-to-Equity Ratio0.08 Current Ratio1.25 Quick Ratio0.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.86 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book3.25Profitability EPS (Most Recent Fiscal Year)($0.39) Net Income$-23,930,000.00 Net Margins-91.61% Return on Equity-64.91% Return on Assets-42.94%Miscellaneous Employees171 Outstanding Shares62,790,000Market Cap$108.00 million Next Earnings Date8/13/2019 (Estimated) OptionableOptionable Veru (NASDAQ:VERU) Frequently Asked Questions What is Veru's stock symbol? Veru trades on the NASDAQ under the ticker symbol "VERU." How were Veru's earnings last quarter? Veru Inc (NASDAQ:VERU) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The company had revenue of $6.98 million for the quarter, compared to analyst estimates of $6.98 million. Veru had a negative return on equity of 64.91% and a negative net margin of 91.61%. View Veru's Earnings History. When is Veru's next earnings date? Veru is scheduled to release their next quarterly earnings announcement on Tuesday, August 13th 2019. View Earnings Estimates for Veru. What guidance has Veru issued on next quarter's earnings? Veru updated its FY 2019 earnings guidance on Wednesday, May, 15th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29-32 million, compared to the consensus revenue estimate of $28.09 million. What price target have analysts set for VERU? 5 equities research analysts have issued 12-month price targets for Veru's shares. Their predictions range from $4.50 to $6.00. On average, they expect Veru's share price to reach $5.1250 in the next year. This suggests a possible upside of 198.0% from the stock's current price. View Analyst Price Targets for Veru. What is the consensus analysts' recommendation for Veru? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Veru. What are Wall Street analysts saying about Veru stock? Here are some recent quotes from research analysts about Veru stock: 1. According to Zacks Investment Research, "Veru Inc. engages in the development, manufacture and marketing of consumer health care products. It focuses on producing FC2 female condom which provides dual protection against unintended pregnancy and sexually transmitted infections. Veru Inc., formerly known as The Female Health Company, is headquartered in Miami, FL. " (4/17/2019) 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $295M. This includes a discounted cash flow-based asset value of $305M for FC2 and Tamsulosin DRS, excluding $10M debt and using a 15% discount rate, 0% terminal growth rate and 60% probability of success for Tamsulosin DRS." (1/23/2019) 3. Maxim Group analysts commented, "Veru announced the company was awarded 75% of the South Africa female condom tender, or a total of 120M female condoms over three years. We view this news as a significant positive, as it will continue to help offset the R&D burn associated with the urology pipeline, which is where we see the most significant value and upside in Veru." (8/27/2018) Has Veru been receiving favorable news coverage? News articles about VERU stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Veru earned a news impact score of 2.6 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Veru's key competitors? Some companies that are related to Veru include Arcus Biosciences (RCUS), Sorrento Therapeutics (SRNE), Albireo Pharma (ALBO), Dynavax Technologies (DVAX), DiaMedica Therapeutics (DMCAF), Cyclerion Therapeutics (CYCN), Kalvista Pharmaceuticals (KALV), CareTech (CTH), Alliance Pharma (APH), SI-Bone (SIBN), Agenus (AGEN), GenMark Diagnostics (GNMK), Achillion Pharmaceuticals (ACHN), Community Health Systems (CYH) and Collegium Pharmaceutical (COLL). What other stocks do shareholders of Veru own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Corbus Pharmaceuticals (CRBP), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Biocept (BIOC), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Iovance Biotherapeutics (IOVA), Opko Health (OPK), Sorrento Therapeutics (SRNE) and Viking Therapeutics (VKTX). Who are Veru's key executives? Veru's management team includes the folowing people: Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)Mr. O. B. Parrish, Co-Founder & Director (Age 86)Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51) Who are Veru's major shareholders? Veru's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.22%), Raymond James & Associates (0.20%), Renaissance Technologies LLC (0.15%), Virtu Financial LLC (0.10%), Northern Trust Corp (0.09%) and Charles Schwab Investment Management Inc. (0.05%). Company insiders that own Veru stock include Daniel Haines, Elgar Peerschke, Harry Fisch, Jesus Socorro, K Gary Barnette and Mitchell Shuster Steiner. View Institutional Ownership Trends for Veru. Which institutional investors are buying Veru stock? VERU stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Raymond James & Associates, Charles Schwab Investment Management Inc., Renaissance Technologies LLC, BlackRock Inc. and Northern Trust Corp. Company insiders that have bought Veru stock in the last two years include Daniel Haines, Elgar Peerschke, Harry Fisch, Jesus Socorro, K Gary Barnette and Mitchell Shuster Steiner. View Insider Buying and Selling for Veru. How do I buy shares of Veru? Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Veru's stock price today? One share of VERU stock can currently be purchased for approximately $1.72. How big of a company is Veru? Veru has a market capitalization of $108.00 million and generates $15.86 million in revenue each year. The company earns $-23,930,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis. Veru employs 171 workers across the globe. What is Veru's official website? The official website for Veru is http://www.veruhealthcare.com/. How can I contact Veru? Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected] MarketBeat Community Rating for Veru (NASDAQ VERU)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 168 (Vote Outperform)Underperform Votes: 113 (Vote Underperform)Total Votes: 281MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: How to calculate compound interest Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.